Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 196.56% from the company’s current price. […]
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 196.56% from the company’s current price. […]
